Switch theme
Sign up to access all valuation multiples
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team’s deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
2021
52
Last FY Revenue n/a
LTM EBITDA -$86.9M
$551M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ArriVent BioPharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$86.9M.
In the most recent fiscal year, ArriVent BioPharma achieved revenue of n/a and an EBITDA of -$94.3M.
ArriVent BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ArriVent BioPharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$86.9M | XXX | -$94.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$112M | XXX | -$94.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$98.7M | XXX | -$80.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ArriVent BioPharma's stock price is $21.
ArriVent BioPharma has current market cap of $727M, and EV of $551M.
See ArriVent BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $551M | $727M | XXX | XXX | XXX | XXX | $-2.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ArriVent BioPharma has market cap of $727M and EV of $551M.
ArriVent BioPharma's trades at n/a EV/Revenue multiple, and -5.8x EV/EBITDA.
Equity research analysts estimate ArriVent BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ArriVent BioPharma has a P/E ratio of -7.4x.
See valuation multiples for ArriVent BioPharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $727M | XXX | $727M | XXX | XXX | XXX |
| EV (current) | $551M | XXX | $551M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.3x | XXX | -5.8x | XXX | XXX | XXX |
| EV/EBIT | -4.9x | XXX | -5.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.4x | XXX | -9.0x | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | -7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArriVent BioPharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
ArriVent BioPharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ArriVent BioPharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ArriVent BioPharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ArriVent BioPharma acquired XXX companies to date.
Last acquisition by ArriVent BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . ArriVent BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ArriVent BioPharma founded? | ArriVent BioPharma was founded in 2021. |
| Where is ArriVent BioPharma headquartered? | ArriVent BioPharma is headquartered in United States of America. |
| How many employees does ArriVent BioPharma have? | As of today, ArriVent BioPharma has 52 employees. |
| Who is the CEO of ArriVent BioPharma? | ArriVent BioPharma's CEO is Dr. Zhengbin Yao, PhD. |
| Is ArriVent BioPharma publicy listed? | Yes, ArriVent BioPharma is a public company listed on NAS. |
| What is the stock symbol of ArriVent BioPharma? | ArriVent BioPharma trades under AVBP ticker. |
| When did ArriVent BioPharma go public? | ArriVent BioPharma went public in 2024. |
| Who are competitors of ArriVent BioPharma? | Similar companies to ArriVent BioPharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ArriVent BioPharma? | ArriVent BioPharma's current market cap is $727M |
| Is ArriVent BioPharma profitable? | Yes, ArriVent BioPharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ArriVent BioPharma? | ArriVent BioPharma's last 12 months EBITDA is -$86.9M. |
| What is the current EV/EBITDA multiple of ArriVent BioPharma? | Current EBITDA multiple of ArriVent BioPharma is -6.3x. |
| What is the current FCF of ArriVent BioPharma? | ArriVent BioPharma's last 12 months FCF is -$95.3M. |
| What is the current EV/FCF multiple of ArriVent BioPharma? | Current FCF multiple of ArriVent BioPharma is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
